FGF2 and colonic neoplasm: observed that a significant upregulation of VEGF and downregulation of β-FGF and ANG1 in colon cancer-derived endothelial cells treated with bevacizumab alone, which might activate a potential self-regulating mechanism of angiogenic growth factors and also explained why current antiangiogenic therapy with bevacizumab alone has limited effects in prolonging the survival of colon cancer patients (27).